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Summary
Purpose. This Phase III randomized multicenter trial compared progression-free (PFS) and overall survival (OS)
for autologous peripheral blood stem cell (aPBSC) transplantation with or without immunotherapy in high-risk
breast cancer patients.
Methods. Eligible patients had American Joint Committee on Cancer (AJCC) 5th Edition Stage II/IIIA with
‡ 4 axillary nodes, Stage IIIB, or chemotherapy-sensitive or stable Stage IV disease. Following treatment with
cyclophosphamide, thiotepa and carboplatin (STAMP V), patients were randomized to aPBSC transplant with
or without immunotherapy. Patients on immunotherapy received cells that were incubated in interleukin-2 (IL-2)
for 24 h followed by parenteral IL-2 for 5 days then 2 days of rest for 4 weeks.
Results. Fifty-nine patients were treated (35 Stage II/IIIA; 13 Stage IIIB; 11 Stage IV), 30 patients were
randomized to immunotherapy and 29 patients to no immunotherapy. Neutrophils engrafted a median of
10 days post-transplant in both groups. The median times to platelet engraftment were 9 and 10 days after
transplant in the no-immunotherapy and immunotherapy groups, respectively (p = 0.03). There was no sta-
tistical evidence (p = 0.61) of a difference in progression-free and surviving (PFS) at 3 years for patients
receiving immunotherapy (53%) compared with no immunotherapy (48%). There was some evidence of supe-
riority in overall survival (OS) at 3 years for patients receiving immunotherapy (83%) compared with no
immunotherapy (69%), but the difference between survival curves was not statistically significant (p = 0.08).
Also, there was some evidence that patients developing acute graft versus host disease (aGVHD) had superior
PFS (p = 0.02) but not OS (p = 0.19) than patients not developing aGVHD. Toxicities were transient and
similar between groups, with no treatment-related deaths.
Conclusions. This phase III study of high-risk breast cancer patients randomized to immunotherapy or no
immunotherapy demonstrated that a well-tolerated immunotherapy regimen added to aPBSC transplant did not
improve PFS, but there was some improvement in OS, but not by an amount that was statistically significant
(p = 0.08).
Introduction
The role of high dose chemotherapy with peripheral
blood stem cell (PBSC) transplantation for the
treatment of high-risk breast cancer remains contro-
versial [1–8]. Although in vitro data have demon-
strated enhanced cytotoxicity with increasing doses of
chemotherapy, escalation of dose alone is unlikely to
eliminate all malignant cells [9]. Recent clinical trials
question the role of high dose chemotherapy and
bone marrow transplantation and support an urgent
need to develop innovative therapies [10]. Immuno-
therapy following myelosuppressive chemotherapy
provides an attractive modality of non-cross-resistant
tumor cell killing in patients with minimal residual
disease.
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We previously generated activated effector cells in
vitro with 24 h of incubation of PBSC with interleukin-2
(IL-2). In high-risk breast cancer patients, a clinical
syndrome suggestive of cutaneous autologous graft ver-
sus host disease (aGVHD) associated with IL-2 activated
autologous PBSC (aPBSC) transplantation followed by
4 weeks of low dose IL-2 was observed [11–13].
Because of encouraging preclinical and clinical Phase
I and II trial results, a multicenter phase III randomized
clinical trial was designed to compare this immuno-
therapy regimen to a standard transplant regimen [14],
involving cyclophosphamide, thiotepa and carboplatin
(STAMP V). The primary endpoint was progression-
free survival (PFS) and the major objectives were to
compare the PFS and overall survival (OS) between the
two treatment arms. Secondary objectives included
comparison of engraftment and toxicities.
Methods
Patient population, eligibility criteria and staging
evaluation
Women between the ages of 17 and 70 years with AJCC
5th Edition Stage II (T1 or T2 with ‡4 axillary lymph
nodes involved with disease), Stage III (T3 with involved
lymph nodes or T4) or chemotherapy-sensitive or stable
Stage IV disease, were eligible. Patients had to have
adequate bone marrow, liver and renal function, no
history of debilitating cardiac or pulmonary disease, and
a Karnofsky performance status of ‡80%. A left ven-
tricular ejection fraction of ‡50% measured by radio-
nuclide scan and pulmonary function tests
demonstrating a forced expiratory volume (FEV1) of
>70% and a diffusion capacity >60% were needed. No
radiographic evidence of malignant central nervous
system involvement could exist. Negative serologies for
Hepatitis B surface antigen, HIV, and HTLV I, and
histological negative bone marrow aspirate and biopsy
were required. The protocol received institutional review
board approval and all patients signed informed con-
sent.
The initial staging evaluation included a complete
physical examination, chest radiograph, bone scan,
computer tomographs of the head, thorax, abdomen,
and pelvis, electrocardiogram, and audiogram. Labo-
ratory evaluation included a complete blood count with
differential and platelet count, coagulation profile, and
renal, liver, and thyroid function tests. Patients with
measurable disease had baseline tumor measurements
by physical examination and/or radiographic studies.
Peripheral blood stem cell (PBSC) collection and harvest
Prior to priming chemotherapy, a central venous cath-
eter was placed. Paclitaxel (300 mg/m2) was adminis-
tered as an intravenous infusion over 24 h to mobilize
PBSC (Figure 1). Recombinant human granulocyte
colony stimulating factor (rhG-CSF) (5 lg/kg) was
administered subcutaneously 48 h after priming che-
motherapy administration and continued daily until
apheresis completion. Complete blood counts were ob-
tained every other day until the start of leukapheresis.
PBSC collection began 24 h after the white blood
count (WBC) returned to 1 · 109/l. Cells were collected
using a Cobe Spectra Cell Separator (Cobe Laborato-
ries, Lakewood, Colorado) with Anticoagulant Citrate
Dextrose–formula A (ACD-A) (Baxter Healthcare,
Deerfield, IL). Three to four whole blood volumes
(10–20 l) were processed for each collection. Leuka-
pheresis continued until 3 · 106 CD34+ cells/kg and
7.5 · 108 mononuclear cells/kg of body weight were
obtained. Clonogenic progenitor cell assays were per-
formed for each collection. Concentrated cell suspen-
sions were cryopreserved in medium consisting of 6%
Pentastarch (McGaw, Irvine, CA), 5% DMSO (Cryo-
serv, Research Industries, Salt Lake City, UT), 4% hu-
man serum albumin (American Red Cross, Washington,
DC), and either sterile endotoxin- tested bovine pan-
creatic DNase (Sigma Chemicals, St. Louis, MO) or
recombinant human DNase (Pulmozyme, Genentech,
San Francisco, CA). Cells were frozen in Cryocyte bags
(Baxter Healthcare) and stored in liquid nitrogen.
Interleukin-2 activation of PBSC
IL-2 activation of PBSC has been described previous
[15] Briefly, harvested cells were thawed rapidly in a
37 C water bath and incubated for 24 h. Incubation
was in 5% CO2 at 37 C in the serum-free medium X-
VIVO 10 (BioWhittaker, Walkersville, MD) containing
gentamicin (50 ug/ml), L-glutamine, heparin (50 units/
ml) (Elkins-Simm, Inc., Cherry Hill, NJ) and IL-2
(6000 IU/ml) (Chiron, Emeryville, CA). Samples were
obtained from the thawed cell suspension prior to and
following IL-2 activation and analyzed for cell count,
viability, Gram stain, immunophenotyping, cytotoxicity
assays and sterility. Approximately one third of the
PBSC were stored for backup without IL-2 culturing.
Treatment plan
Cyclophosphamide (1500 mg/m2), carboplatin (200
mg/m2) and Thiotepa (125 mg/m2) each were admin-
istered intravenously over 2 h for 4 days on days )6 to
)3. MESNA (sodium 2-mercaptoethane sulfonate) and
hydration were given as prophylaxis for hemorrhagic
cystitis. The anti-emetic regimen included ondansetron,
lorazepam, and diphenhydramine.
On day 0, the PBSC were infused over 30–90 min
at the patients bedside with cardiovascular monitor-
ing. Patients randomized to no immunotherapy
received no further treatment. Patients randomized to
immunotherapy received subcutaneous IL-2 (Chiron
Therapeutics, California) the same day and continued
p
126 C Isaacs et al.
for 4 weeks [11] IL-2 began at 6 · 105 IU/m2/d, based
on previous clinical trials [11,13]. A week of therapy
was 5 days of treatment and 2 days of rest.
Engraftment was defined as an absolute neutrophil
count of ‡500/mm3 for 3 days and a platelet count of
‡20 · 109/l for 3 days (untransfused).
Toxicities were monitored daily and graded
according to CALGB Toxicity Criteria as follows:
Grade 0 (no toxicity), Grade 1 (mild), Grades 2 and
3 (moderate), Grade 4 (severe) and Grade 5 (toxic
death). IL-2 was held if severe non-hematologic tox-
icities occurred during therapy. If the toxicities re-
turned to Grade 1 or resolved within 48 h, IL-2 was
resumed. If signs and symptoms of the non-hemato-
logic toxicities returned after resolution or failed to
improve in 72 h, the IL-2 was discontinued but the
patient remained on study.
Evaluation of skin for GVHD
Since prior clinical trials using this immunotherapy
regimen demonstrated signs consistent with skin
aGVHD, each patient received a daily skin exam by a
bone marrow transplant physician during their
in-hospital stay. Individuals randomized to immuno-
therapy treatment at Georgetown University Medical
Center (GUMC) additionally were to receive a 4-mm
skin punch biopsy prior to initiation of week 3 ther-
apy. All biopsy specimens were graded for the pres-
ence or absence of 4 histologic criteria using a scale
developed by Horn [16] including basal cell vacuoli-
zation, exocytosis, dyskeratotic cells and dermal lym-
phatic infiltration by a dermatopathologist blinded to
the treatment the patient was receiving. Skin biopsy
specimens demonstrating ‡3 criteria were considered
compatible with aGVHD.
Supportive care
Patients were treated in HEPA-filtered rooms. Routine
supportive care was started at the time of admission and
included Norfloxacin for gastrointestinal bacterial
decontamination, Fluconazole, and Acyclovir (both
continued until day 30). With the development of a
temperature ‡38.5 C, broad-spectrum antibiotics were
initiated and Norfloxacin was discontinued. Ampho-
tericin B was administered empirically when patients
remained febrile after 48–72 h on broad-spectrum anti-
biotic therapy. All patients received daily rhG-CSF
(5 lg/kg/day) beginning on day 5 after transplantation
until the absolute neutrophil count (ANC) reached
5.0 · 109/l for 2 days.
In-hospital clinical monitoring
Patients underwent daily physical examination and
blood work, including a complete blood count with
differential and platelet count, electrolytes, and liver and
renal function tests. Packed red blood cells and platelets
were administered if the hemoglobin level fell below
8.5 g/dl, platelets dropped below 20 · 109/l, or for
symptomatic anemia or bleeding.
Clinical monitoring after discharge
Patients were evaluated weekly in the outpatient clinic
for 1 month before returning to their referring oncolo-
gist. Evaluation at each clinic visit included a history and
physical examination, a complete blood count with dif-
ferential and platelet count, electrolytes, liver and renal
function tests. Response was evaluated 100 days after
transplantation by physical examination, bone scan and
CT scans of the thorax, abdomen and pelvis. Re-evalu-
ation was performed every 6 months for the first 2 years
and yearly thereafter. Patients with inflammatory breast
cancer or 4 or more axillary lymph nodes involved with
metastatic carcinoma received irradiation of the ipsilat-
eral chest wall, supraclavicular, and axillary areas
beginning 3 months post-transplantation (total dose
5040 cGy chest wall). Patients with estrogen receptor
(ER) positive tumors started on Tamoxifen (20 mg twice














Abbreviations: CTCb=cyclophosphamide, Thiotepa, carboplatin
 PBSC=peripheral blood stem cells
** Stage IV patients will receive IL-2 at 1.8 x 106 I.U./m2/d
   5 days every month until progression
Figure 1. Trial Schema. 30 Patients were randomized to immuno-
therapy and 29 patients to no immunotherapy. All randomized pa-
tients received transplant.
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Statistical considerations
Design of the study
This randomized, phase III clinical trial was stratified by
disease stage (II–IIIA, IIIB, and IV) and conducted at
multiple institutions. The trial was designed to determine
whether patients receiving additional immunotherapy
with subcutaneous IL-2 cells (immunotherapy group)
would demonstrate improved PFS at 3 years compared
with patients receiving combined therapy and transplant
with PBSCs alone (no-immunotherapy group). Origi-
nally, 195 patients were to be accrued and followed for
3 years to detect an odds ratio (OR) for PFS of 2.0 or
more over all strata with statistical power of 80% at a 5%
significance level (two-sided test). In stratum Stage
II–IIIA, an OR of 2.0 would mean an improvement in
3-year PFS from 60% for the no-immunotherapy group
to 75% for the immunotherapy group, and there would
be similar amounts of improvement in PFS in the other
stages. Secondary endpoints included OS, hematopoietic
reconstitution, and toxicity.
Conduct of the study
Between December 1997 and December 2000, 59 pa-
tients were accrued by Georgetown University Medical
Center (GUMC) (n = 45), University of Massachusetts
Memorial Hospital (n = 8) and Holy Cross Hospital
(n = 6). Patients were stratified by stage of disease and
randomized equally to the two treatment arms. A bio-
statistician prepared the randomization list that was
concealed from other study personnel. At completion of
mobilization treatment, the research nurse provided the
patients disease stage to the biostatistician for ran-
domization. Study personnel and patients were un-
blinded to treatment after randomization since different
procedures were required for immunotherapy treatment.
The dermatopathologist was blinded to treatment arm
(immunotherapy versus not) for aGVHD ascertainment.
In accord with NCI requirements for phase III clin-
ical trials, an independent Data Monitoring Committee
(DMC) was organized, that included one biostatistician
and two clinicians. The DMC met in January 1999 and
December 2000 and recommended termination of the
study following the latter meeting. The major reason for
termination was a marked drop in patient accrual fol-
lowing publications questioning the role of transplan-
tation for breast cancer [1,6,17].
Analysis of the study
PFS, OS, and post-progression survival (PPS) curves
were calculated using the Kaplan–Meier [18] method.
PFS was defined as the time from randomization to
progression, death, or date of last follow-up, whichever
came first. Overall survival was the time between ran-
domization and date of death or last contact. Patients
surviving progression-free were censored at the date of
last contact for PFS. PPS, the time between progression
and date of death or last follow-up, included only pa-
tients who progressed. Survival curves for all patients
were compared by the generalized Wilcoxon test [19]
since hazard rates were not proportional between
groups. Survival curves were also calculated for subsets
of patients by stage and by aGVHD without adjustment
of p-values since interpretation of outcomes was based
upon patients from all stages combined. The combina-
tion of treatment and aGVHD effects on PFS and OS
was explored with Coxs proportional hazards regres-
sion [20]. Standard v2 tests were used to compare the
distributions of patients and incidence rates (e.g. toxic-
ity) between groups. All statistical tests were two-sided
with a 0.05 significance level. Analyses were performed
using the ‘intention-to-treat principle. The Haybittle–
Peto approach to the analysis of accumulating data was
planned with interim tests to be performed at a 0.001
significance level, assuring that the final test would be
nearly at the 0.05 level. No interim analyses of efficacy
were performed prior to termination of the study.
Results
Patient characteristics
Fifty-nine patients with a median age of 49 years (range
32–66 years) were treated. Thirty patients were ran-
domized to receive immunotherapy and the remaining
29 patients to receive standard aPBSC transplant ther-
apy. Table 1 presents patient demographics and the
comparability of the two treatment groups. In addition
to stage which was a stratification factor, patients had
comparable distributions of age group, ER and PR
status, and race.
Engraftment
All patients engrafted, so backup stem cell infusion was
not needed. The median number of days required for the
absolute neutrophil count (ANC) to maintain 500/mm3
for 32 days was 10 days in both treatment groups (range
8–12 days). Platelet engraftment occurred at median of
9 days post-transplant (range 6–22 days) for the no-
immunotherapy arm and day 10 (range 6–25 days) in the
immunotherapy arm (p = 0.03).
Withdrawal from immune therapy
Six of the 30 patients randomized to receive immuno-
therapy were removed from IL-2 due either to infection
(n = 5) or patients desire (n = 1). The median dura-
tion of IL-2 therapy for these six patients was 14 days
(range: 4–21 days).
Progression-free Survival, overall survival, and
post-progression survival
The median follow-up time for surviving patients was
56 months. Figure 2a gives the PFS curves by
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treatment. Although the PFS curves appeared to
separate during the first 18 months, they converged by
24 months and there was no statistical evidence of
differing PFS times between groups (p = 0.61). The
3-year PFS was 53% (SE = 9%) in the immuno-
therapy group and 48% (SE = 9%) in the
no-immunotherapy group.
Figure 2b gives the OS curves by treatment group
and, subsequent to 1 year, the immunotherapy group
had superior survival. At 3 years, the OS was 83%
(SE = 7%), in the immunotherapy group and 69%
(SE = 9%) in no-immunotherapy group. The appar-
ent visual advantage in OS for the immunotherapy
group did not achieve statistical significance at the 5%
level (p = 0.08). Of the 23 deaths on the study, 14
were in the no-immunotherapy group.
Figure 2c gives the PPS curves for progressed
patients. The median post-progression follow-up time
among surviving patients was 18 months. The 18-month
survival post-progression was 62% (SE = 12%) in the
immunotherapy group and 44% (SE = 13%) in the no-
immunotherapy group. The difference between curves
was not significant (p=0.13), and the p-value was
identical to that in Figure 2b for the OS curves. The
apparent difference in OS experience from the time of
randomization between the immunotherapy and no
immunotherapy arms was due primarily to longer sur-
vival post-progression in the immunotherapy group.
Progression-free survival and overall survival based on
disease stages
Figure 3a and 3b provide the PFS and OS experience by
treatment for the 35 Stage II–IIIA patients, the largest
subgroup. While the initial trial design included a
stratification by disease stage, the actual number of
patients in each disease stage was quite small given the
early termination of the study secondary to poor accrual
to transplant trials. In Figure 3a, the estimated PFS at
Table 1. Comparability of patients by treatment Arm
Patient Characteristics Treatment
All N (%) Immunotherapy N (%) No Immunotherapy N (%) p-value*
All Patients 59 (100) 30 (51) 29 (49)
Stage
II–IIIA 35 (59) 18 (60) 17(59)
IIIB 13 (22) 6 (20) 7 (24)
IV 11 (19) 6 (20) 5 (17)
Age (Yrs.) >0.99
30–39 10 (17) 5 (17) 5 (17)
40–49 24 (41) 12 (40) 12 (41)
50–59 20 (34) 10 (33) 10 (34)
60–69 5 (8) 3 (10) 2 (7)
Treatment Site 0.18
LCC 45 (76) 24 (80) 21 (72)
HCH 6 (10) 1 (3) 5 (17)
UMA 8 (14) 5 (17) 3 (10)
ER Status 0.20
+ 29 (49) 15 (50) 14 (48)
) 24 (41) 14 (47) 10 (34)
UNK 6 (10) 1 (3) 5 (17)
PR Status 0.21
+ 27 (46) 14 (47) 13 (45)
- 26 (44) 15 (50) 11 (38)
UNK 6 (10) 1 (3) 5 (17)
Race 0.17
African-American 7 (12) 2 (7) 5 (17)
Asian 2 (4) 0 (0) 2 (7)
Caucasian 48 (81) 26 (87) 22 (76)
Hispanic 1 (2) 1 (3) 0 (0)
Other 1 (2) 1 (3) 0 (0)
LCCC = Lombardi Comprehensive Cancer Center, Georgetown University Medical Center; HCH = Holy Cross Memorial Hospital; UMA
= University of Massachusetts Memorial Medical Center; ER = Estrogen Receptor; PR = Progesterone Receptor; UNK = Unknown or
Missing.
*The p-value is provided to indicate a level of difference between the two groups. However, the interpretation is not based on determining if these
differences occurred at random since the study was randomized, so all differences occurred at random.
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3 years in the immunotherapy group was 61%
(SE = 11%) compared with 46% (SE = 12%) in the
no-immunotherapy group, but the difference between
curves was not statistically significant (p = 0.34).
Figure 3b gives the survival curves by treatment in Stage
II–IIIA patients, showing some advantage in survival
for patients receiving immunotherapy (p = 0.05). At
3 years, 83% (SE = 9%) of patients were surviving in
the immunotherapy group compared with 64% (SE
= 12%) in the no-immunotherapy group.
The PFS at 3 years for the 13 stage IIIB patients was
50% (SE = 20%) in the immunotherapy group and
43% (SE = 19%) in the no-immunotherapy group
(p = 0.84). The percent of stage IIIB patients surviving
at 3 years was 83% (SE = 15%) in the immunotherapy
group and 86% (SE = 13%) in the no-immunotherapy
group (p = 0.91; curves not shown).
There were only 11 patients with Stage IV disease in
the study. Patients with Stage IV disease receiving
immunotherapy had 33% PFS at 2 years (33%; SE
= 19%) compared to 60% (SE = 22%) in the no-
immunotherapy arm, but the difference between curves
was not significant (p = 0.38). The OS curves were
similar for the immunotherapy and no-immunotherapy
groups, with 3-year estimates of the percent surviving of
63% (SE = 21%) and 60% (SE = 22%), respectively
(p = 0.87; curves not shown).
Evaluation of cutaneous aGVHD
Of the 45 patients treated at GUMC, 33 received 4 mm
punch skin biopsies upon engraftment, 16 (48%) who
were classified as having aGVHD and 17 patients
without. There was a higher percent of patients with
aGVHD in the no-immunotherapy arm (67%; 8/12)
compared to the immunotherapy arm (38%; 8/21), but
this difference was not significant (p = 0.16). Figure 4a
shows a statistically significant advantage in PFS for
patients with aGVHD (p = 0.02). The 3-year PFS was
75% (SE = 11%) for the aGVHD patients compared
with 29% (SE = 11%) for the patients without
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Figure 2. All patients. Progression-free (a), overall (b), and post pro-






















































































































Figure 3. Stages II–IIIA. Progression-free (a) and overall (b) survival
for patients with stages II–IIIA in the immunotherapy (solid), and no-
immunotherapy (dashed) groups.
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aGVHD (p = 0.02). Survival curves for patients who
had or did not have aGVHD are shown in Figure 4b.
There was no statistically significant difference between
the curves (p = 0.19), the percent of patients surviving
3 years being 94% (SE = 6%) for the aGVHD pa-
tients and 76% (SE = 10%) for patients not having
aGVHD.
Cox regression models were fit to both the PFS and
OS data including factors for treatment and occurrence
of aGVHD (no or yes). In the model for PFS, the type
of treatment was not statistically significant (p = 0.67),
however occurrence of aGVHD was statistically signif-
icant (p = 0.02). Neither treatment nor aGVHD status
was significantly associated with OS in the Cox model.
With only 33 patients that were classified for aGVHD,
additional studies are needed to confirm the prognostic
value of aGVHD.
The incidence of in-hospital moderate (grade 3)
or severe toxicities (grade 4)
There were no toxic deaths and all side effects were
self-limiting. Toxicities are presented by treatment arm
with severity in Table 2. There was no statistical dif-
ference in incidence of grades 3 and 4 toxicities be-
tween the two groups. No grade 4 non-hematologic
toxicities occurred in the immunotherapy arm. Three
patients experienced Grade 4 toxicities in the no-
immunotherapy arm, consisting of diarrhea, dyspha-
gia, stomatitis, or skin rash.
Cause of death
With the median follow-up time among surviving
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Figure 4. aGVHD. Progression-free (a) and overall (b) survival for
patients with punch biopsies with (solid), and without (dashed) aG-
VHD.
Table 2. Numbers (and percentages) of patients experiencing moderate (grade 3) or severe (grade 4) toxicities
Toxicity Immunotherapy N = 30 No Immunotherapy N = 29
Grade Grade
3 4 3 4
N (%) N (%) N (%) N (%)
Cardiac 1 (3) 0 (0) 1 (3) 0 (0)
Esophagitis/stomatitis 2 (7) 0 (0) 2 (7) 2* (7)
Flu-like symptoms 4 (14) 0 (0) 2 (7) 0 (0)
GI symptoms 2 (7) 0 (0) 3** (10) 1 (3)
Infection 3 (10) 0 (0) 4 (14) 0 (0)
Liver transaminase 1 (3) 0 (0) 0 (0) 0 (0)
Metabolic abnormalities 4 (14) 0 (0) 3 (10) 0 (0)
Coagulation 0 (0) 0 (0) 0 (0) 1 (3)
Phlebitis/ thrombosis Embolism 0 (0) 0 (0) 1 (3) 0 (0)
Pulmonary 1 (3) 0 (0) 1 (3) 0 (0)
Skin 1 (3) 0 (0) 1 (3) 1 (3)
Metabolic abnormalities = Hyperglycemia, hypocalcemia, hypomagnasemia, or hyponatremia. Flu-like symptoms = Fever without infection,
Malaise/fatigue, or pain. GI symptoms = Anorexia, diarrhea, or nausea.
*One patient had grade 4 toxicities for both esophagitis and stomatitis; she is counted only once here, but there are a total of 3 grade four
toxicities in this category.
**Two patients each had grade 3 toxicities for both anorexia and nausea. Each patient is only counted once here, but there are a total of 5 grade
three toxicities in this category. Grade 4 = severe/life-threatening toxicity.
Immunotherapy and PBSC transplant for breast cancer 131
patients randomized to immunotherapy and 14 patients
who were not. Of the patients expiring on immuno-
therapy, 7 patients died of tumor and 2 patients had
unknown cause of death. Of the 14 patients not
receiving immunotherapy, 13 died a known tumor-re-
lated death.
Discussion
The regimen using IL-2 activation of PBSCs and IL-2
following transplantation demonstrated some improve-
ment in OS compared to standard aPBSC therapy in
these high risk breast cancer patients that was not sta-
tistically significant (p = 0.08). This trial was planned
to accrue 195 patients in order to detect a significant
difference between the treatment arms (odds ratio for
PFS of 2.0 or greater with statistical power of 80% at a
5% significance level). Due to the marked drop in
enthusiasm for high dose chemotherapy and stem cell
transplant in patients with breast cancer, only 59
patients were accrued before the study termination was
recommended by the independent data safety monitor-
ing board. Thus, any conclusions reached from this trial
are underpowered, and must be viewed as tentative.
There was no difference in PFS between the treatment
groups so the difference in OS was due primarily to
patients who received IL-2 living longer post-progres-
sion than patients without IL-2. For skin biopsy
patients, aGVHD was associated with longer PFS
(p = 0.02), but not OS (p = 0.19). Toxicities, aGVHD,
and neutrophil engraftment were similar between arms.
Platelet engraftment was delayed one day in the immu-
notherapy arm.
Immunotherapy following aPBSC transplantation
has been shown to generate aGVHD in patients with
breast cancer, multiple myeloma, lymphoma and acute
myelogenous leukemia [11,13,21–28]. In the allogeneic
bone marrow transplant setting, the presence of GVHD
is associated with a GVT effect, possibly contributing to
lower relapse rates [29,30]. The co-existence of an
autologous GVT effect among patients experiencing
aGVHD remains unknown.
The mechanism of action for the immunotherapy in
this protocol differs from other regimens. Researchers at
Johns Hopkins have used cyclosporin and c-IFN post-
transplant. It is postulated that the c-IFN upregulates
MHC Class II expression, while the cyclosporin pre-
vents the deletion of auto-reactive lymphocytes. As a
result, the auto-reactive lymphocytes recognize and
attack the patients cells with the enhanced MHC Class
II expression.
Incubation of hematopoietic cells with IL-2 in vitro
for 24 h generates cytotoxic effector cells [21,22,26,31].
These activated cells lyse NK-sensitive and NK-resistant
tumor cells and result in in vitro purging [32,33]. Addi-
tionally, infusion of IL-2 activated aPBSC followed by
low doses of parenteral IL-2 reduces tumor cell con-
tamination within the graft and generates cytotoxic
effector cells that may mediate a GVT effect in vivo
[34–36].
Prior to implementing IL-2 activation of stem cells in
clinical trials, growth and differentiation of hematopoi-
etic progenitor cells had to remain unaffected. When
bone marrow or peripheral blood stem cells are acti-
vated in IL-2 in long-term (7 days) and short-term
(1 days) culture, there is no decrease in colony-forming
cells, when analyzed by clonogenic assays [15,36].
A previous Phase I–II Clinical Trial with 61 patients
demonstrated that the in vitro activation of aPBSC with
IL-2 for transplantation followed by the same day par-
enteral administration of IL-2 did not delay engraftment
and was associated with mild to moderate toxicities in
Stage II–IV breast cancer patients [13]. In addition,
some of these patients demonstrated signs and symp-
toms of cutaneous aGVHD [12]. The IL-2 activated
bone marrow has significant anti-tumor activity in vitro
and in vivo with no detrimental effect on hematopoiesis
[35]. Previous breast cancer clinical trials using IL-2
activation of PBSC combined with parenteral IL-2 or
the combination of IL-2 with a-IFN post-transplant,
revealed no detrimental effect on hematopoiesis or
engraftment [12,37].
Forty-eight hours or more of IL-2 incubation of
peripheral blood mononuclear cells is required to gen-
erate lymphokine activated killer (LAK) cells [15,26,38].
This clinical trial utilized 24 h of IL-2 activation of
PBSC to induce cytotoxic effector cells, suggesting that
different cells may be involved. Although others have
demonstrated the importance of T cell subsets in short-
term IL-2 activation, especially CD4+ and CD8+ T
cells [38], our results demonstrate that the majority of
effector cells generated with 24-h IL-2 incubation are
CD8+ T cells, CD56+ NK cells, and possibly,
CD8+CD56+ cells [39]. Recent evidence shows that
5–30% of CD8+ T cells co-express CD56 NK marker
[40]. The cytokine-induced killer (CIK) cell, a cell pos-
sessing the combination of T cell markers (CD3+) and
NK cell marker (CD56+) may also play a role, since the
CD3+CD56+ cells also contributed to cytotoxicity
[41,42]
The role of aPBSC transplantation for high-risk
breast cancer patients has not yet been clearly defined
[43]. Because of publications questioning the role of
transplantation for breast cancer, accrual to this trial
dropped markedly, causing the investigators to termi-
nate patient accrual early, as recommended by the
DMC. Although patients receiving immunotherapy
experienced improved OS with median follow-up of
56 months in surviving patients, especially patients with
Stage II–IIIA disease, the number of patients is small
and there was no evidence of an improvement in PFS.
These intriguing results from combining immunother-
apy with myelosuppressive chemotherapy should
be considered in the design of future clinical trials for
high-risk breast cancer patients. Additionally, the rela-
tionship of outcome with aGVHD deserves further
exploration.
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